insulin-like growth factor-binding protein-3
Recombinant proteinexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2005 (NCT00233519)
Timeline
Indications
Mechanism of action
- Insulin-like growth factor I receptorSupplementation
IGF1R supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- insulin-like growth factor-binding protein-3
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02386839 | Phase 2 | Mar 26, 2015 | Shire, Takeda |
| NCT00233519 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2005 | Insmed, Inc., National Institute of Neurological Disorders and Stroke (NINDS), University of Rochester |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Insmed, Inc. | For profit | 1 | 0 | 1 | 2005 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 1 | 0 | 1 | 2005 |
| Shire | For profit | 1 | 1 | 1 | 2015 |
| Takeda | For profit | 1 | 0 | 1 | 2015 |
| University of Rochester | Academic/Hospital | 1 | 1 | 1 | 2005 |
5 organizations
Page 1 / 1